BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, Marcellini M, Marchesini G. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther. 2008;30:1168-1176. [PMID: 18640473 DOI: 10.1016/j.clinthera.2008.06.012] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Nobili V, Socha P. Pediatric Nonalcoholic Fatty Liver Disease: Current Thinking. Journal of Pediatric Gastroenterology & Nutrition 2018;66:188-92. [DOI: 10.1097/mpg.0000000000001823] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Alisi A, Nobili V. Non-alcoholic fatty liver disease in children now: lifestyle changes and pharmacologic treatments. Nutrition. 2012;28:722-726. [PMID: 22464551 DOI: 10.1016/j.nut.2011.11.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
3 Alisi A, Manco M, Devito R, Nobili V. Fatty Liver Disease. In: Freemark M, editor. Pediatric Obesity. New York: Springer; 2010. pp. 201-22. [DOI: 10.1007/978-1-60327-874-4_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2009;25:230-237. [PMID: 19396962 DOI: 10.1097/MOG.0b013e3283294a18] [Cited by in Crossref: 54] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
5 Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology. 2010;52:370-381. [PMID: 20578153 DOI: 10.1002/hep.23711] [Cited by in Crossref: 97] [Cited by in F6Publishing: 82] [Article Influence: 8.1] [Reference Citation Analysis]
6 Sokolovska J, Isajevs S, Sugoka O, Sharipova J, Lauberte L, Svirina D, Rostoka E, Sjakste T, Kalvinsh I, Sjakste N. Influence of metformin on GLUT1 gene and protein expression in rat streptozotocin diabetes mellitus model. Arch Physiol Biochem 2010;116:137-45. [PMID: 20583965 DOI: 10.3109/13813455.2010.494672] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
7 Pardee PE, Lavine JE, Schwimmer JB. Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery. Semin Pediatr Surg 2009;18:144-51. [PMID: 19573756 DOI: 10.1053/j.sempedsurg.2009.04.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
8 De Bruyne RM, Fitzpatrick E, Dhawan A. Fatty liver disease in children: eat now pay later. Hepatol Int. 2010;4:375-385. [PMID: 20305757 DOI: 10.1007/s12072-009-9160-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
9 Nobili V, Alisi A, Raponi M. Pediatric non-alcoholic fatty liver disease: Preventive and therapeutic value of lifestyle intervention. World J Gastroenterol 2009; 15(48): 6017-6022 [PMID: 20027672 DOI: 10.3748/wjg.15.6017] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
10 Lewis JR, Mohanty SR. Nonalcoholic Fatty Liver Disease: A Review and Update. Dig Dis Sci 2010;55:560-78. [DOI: 10.1007/s10620-009-1081-0] [Cited by in Crossref: 212] [Cited by in F6Publishing: 211] [Article Influence: 17.7] [Reference Citation Analysis]
11 Rafeey M, Mortazavi F, Mogaddasi N, Robabeh G, Ghaffari S, Hasani A. Fatty liver in children. Ther Clin Risk Manag 2009;5:371-4. [PMID: 19536316 DOI: 10.2147/tcrm.s4467] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Brufani C, Fintini D, Nobili V, Patera PI, Cappa M, Brufani M. Use of metformin in pediatric age. Pediatr Diabetes 2011;12:580-8. [PMID: 21366813 DOI: 10.1111/j.1399-5448.2010.00741.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
13 Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1798-1810. [PMID: 27003600 DOI: 10.1053/j.gastro.2016.03.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 11.5] [Reference Citation Analysis]
14 Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;31:679-692. [PMID: 20415840 DOI: 10.1111/j.1365-2036.2009.04230.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 73] [Article Influence: 10.6] [Reference Citation Analysis]
15 Baker PR 2nd, Friedman JE. Mitochondrial role in the neonatal predisposition to developing nonalcoholic fatty liver disease. J Clin Invest 2018;128:3692-703. [PMID: 30168806 DOI: 10.1172/JCI120846] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
16 Della Corte C, Liccardo D, Ferrari F, Alisi A, Nobili V. Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 2014;15:2501-11. [DOI: 10.1517/14656566.2014.960389] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Lindbäck SM, Gabbert C, Johnson BL, Smorodinsky E, Sirlin CB, Garcia N, Pardee PE, Kistler KD, Schwimmer JB. Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review. Advances in Pediatrics 2010;57:85-140. [DOI: 10.1016/j.yapd.2010.08.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
18 Pan CS, Stanley TL. Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. Front Endocrinol (Lausanne) 2020;11:70. [PMID: 32153507 DOI: 10.3389/fendo.2020.00070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
19 Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol 2014;5:177. [PMID: 24795720 DOI: 10.3389/fimmu.2014.00177] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 9.8] [Reference Citation Analysis]
20 Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol 2015; 7(3): 575-582 [PMID: 25848481 DOI: 10.4254/wjh.v7.i3.575] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
21 Juárez-López C, Klünder-Klünder M, Madrigal-Azcárate A, Flores-Huerta S. Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents. Pediatr Diabetes 2013;14:377-83. [PMID: 23438101 DOI: 10.1111/pedi.12024] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
22 Barshop NJ, Francis CS, Schwimmer JB, Lavine JE. Nonalcoholic fatty liver disease as a comorbidity of childhood obesity. Ped Health. 2009;3:271-281. [PMID: 20556232 DOI: 10.2217/phe.09.21] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
23 Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009;49:306-17. [PMID: 19065650 DOI: 10.1002/hep.22603] [Cited by in Crossref: 372] [Cited by in F6Publishing: 347] [Article Influence: 28.6] [Reference Citation Analysis]
24 Alisi A, Nobili V. Nonalcoholic fatty liver disease: Targeted therapy in children--what is the right way? Nat Rev Gastroenterol Hepatol 2011;8:425-6. [PMID: 21750513 DOI: 10.1038/nrgastro.2011.117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
25 Sadeghi A, Mousavi SM, Mokhtari T, Parohan M, Milajerdi A. Metformin Therapy Reduces Obesity Indices in Children and Adolescents: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Child Obes 2020;16:174-91. [PMID: 32068434 DOI: 10.1089/chi.2019.0040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
26 Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2009;16:141-149. [PMID: 19262374 DOI: 10.1097/med.0b013e3283293015] [Cited by in Crossref: 114] [Cited by in F6Publishing: 51] [Article Influence: 8.8] [Reference Citation Analysis]
27 Rook M, Rosenthal P. Caring for adults with pediatric liver disease. Curr Gastroenterol Rep. 2009;11:83-89. [PMID: 19166664 DOI: 10.1007/s11894-009-0013-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
28 Forcheron F, Abdallah P, Basset A, del Carmine P, Haffar G, Beylot M. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. Obesity (Silver Spring). 2009;17:1381-1389. [PMID: 19553925 DOI: 10.1038/oby.2008.661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
29 Faienza MF, Chiarito M, Molina-Molina E, Shanmugam H, Lammert F, Krawczyk M, D'Amato G, Portincasa P. Childhood obesity, cardiovascular and liver health: a growing epidemic with age. World J Pediatr 2020;16:438-45. [PMID: 32020441 DOI: 10.1007/s12519-020-00341-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
30 Manco M. Metabolic syndrome in childhood from impaired carbohydrate metabolism to nonalcoholic fatty liver disease. J Am Coll Nutr 2011;30:295-303. [PMID: 22081615 DOI: 10.1080/07315724.2011.10719972] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
31 Ning HH, Le J, Wang Q, Young CA, Deng B, Gao PX, Zhang HQ, Qin SL. The effects of metformin on simple obesity: a meta-analysis. Endocrine 2018;62:528-34. [PMID: 30151735 DOI: 10.1007/s12020-018-1717-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
32 Tagi VM, Samvelyan S, Chiarelli F. Metabolic syndrome in children. Minerva Pediatr 2020;72:312-25. [PMID: 32274915 DOI: 10.23736/S0026-4946.20.05834-X] [Reference Citation Analysis]
33 Razavizade M, Jamali R, Arj A, Matini SM, Moraveji A, Taherkhani E. The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. Hepat Mon. 2013;13:e9270. [PMID: 23930133 DOI: 10.5812/hepatmon.9270] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
34 Varda NM, Gregoric A. Metabolic syndrome in the pediatric population: a short overview. Pediatr Rep 2009;1:e1. [PMID: 21589817 DOI: 10.4081/pr.2009.e1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
35 Wu M, Xu H, Liu J, Tan X, Wan S, Guo M, Long Y, Xu Y. Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms. J Diabetes Res 2021;2021:6673525. [PMID: 34007848 DOI: 10.1155/2021/6673525] [Reference Citation Analysis]
36 Alisi A, Feldstein AE, Villani A, Raponi M, Nobili V. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012;9:152-61. [DOI: 10.1038/nrgastro.2011.273] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
37 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(7): 1712-1723 [PMID: 24587650 DOI: 10.3748/wjg.v20.i7.1712] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 73] [Article Influence: 9.8] [Reference Citation Analysis]
38 Garinis GA, Fruci B, Mazza A, De Siena M, Abenavoli S, Gulletta E, Ventura V, Greco M, Abenavoli L, Belfiore A. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes 2010;34:1255-64. [DOI: 10.1038/ijo.2010.40] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 5.9] [Reference Citation Analysis]
39 Conjeevaram HS, Tiniakos DG. Exercise for NAFLD: Does Intensity Matter? American Journal of Gastroenterology 2011;106:470-5. [DOI: 10.1038/ajg.2010.496] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
40 Alisi A, Manco M, Vania A, Nobili V. Pediatric Nonalcoholic Fatty Liver Disease in 2009. The Journal of Pediatrics 2009;155:469-74. [DOI: 10.1016/j.jpeds.2009.06.014] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 6.6] [Reference Citation Analysis]
41 Bhat A, Sebastiani G, Bhat M. Systematic review: Preventive and therapeutic applications of metformin in liver disease. World J Hepatol 2015; 7(12): 1652-1659 [PMID: 26140084 DOI: 10.4254/wjh.v7.i12.1652] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
42 Bramlage KS, Bansal V, Xanthakos SA, Kohli R. Fatty liver disease in children--what should one do? Indian J Pediatr 2013;80 Suppl 1:S109-14. [PMID: 22722986 DOI: 10.1007/s12098-012-0826-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
43 Widhalm K, Ghods E. Nonalcoholic fatty liver disease: a challenge for pediatricians. Int J Obes 2010;34:1451-67. [DOI: 10.1038/ijo.2010.185] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
44 Berardis S, Sokal E. Pediatric non-alcoholic fatty liver disease: an increasing public health issue. Eur J Pediatr. 2014;173:131-139. [PMID: 24068459 DOI: 10.1007/s00431-013-2157-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 8.3] [Reference Citation Analysis]
45 Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276-1285. [PMID: 24738701 DOI: 10.1111/apt.12758] [Cited by in Crossref: 232] [Cited by in F6Publishing: 201] [Article Influence: 29.0] [Reference Citation Analysis]
46 Ho M, Garnett SP, Baur LA. Childhood obesity and insulin resistance: how should it be managed? Curr Treat Options Cardiovasc Med 2014;16:351. [PMID: 25293340 DOI: 10.1007/s11936-014-0351-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
47 Merola J, Liapakis A, Mulligan DC, Yoo PS. Non-alcoholic fatty liver disease following liver transplantation: a clinical review. Clin Transplant 2015;29:728-37. [PMID: 26147308 DOI: 10.1111/ctr.12585] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
48 Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol. 2014;5:177. [PMID: 24795720 DOI: 10.3389/fimmu.2014. 00177] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Ode KL, Frohnert BI, Nathan BM. Identification and treatment of metabolic complications in pediatric obesity. Rev Endocr Metab Disord 2009;10:167-88. [PMID: 19809879 DOI: 10.1007/s11154-009-9115-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
50 Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, Mouzaki M, Sathya P, Schwimmer JB, Sundaram SS, Xanthakos SA. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017;64:319-34. [PMID: 28107283 DOI: 10.1097/MPG.0000000000001482] [Cited by in Crossref: 306] [Cited by in F6Publishing: 133] [Article Influence: 76.5] [Reference Citation Analysis]
51 Manco M, Bottazzo G, Devito R, Marcellini M, Mingrone G, Nobili V. Nonalcoholic Fatty Liver Disease in Children. Journal of the American College of Nutrition 2008;27:667-76. [DOI: 10.1080/07315724.2008.10719744] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
52 Anderson EL, Fraser A, Howe LD, Callaway MP, Sattar N, Day C, Tilling K, Lawlor DA. Physical Activity Is Prospectively Associated With Adolescent Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr 2016;62:110-7. [PMID: 26252921 DOI: 10.1097/MPG.0000000000000904] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Goldner D, Lavine JE. Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges. Gastroenterology. 2020;158:1967-1983.e1. [PMID: 32201176 DOI: 10.1053/j.gastro.2020.01.048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
54 AlKhater SA. Paediatric non-alcoholic fatty liver disease: an overview. Obes Rev 2015;16:393-405. [PMID: 25753407 DOI: 10.1111/obr.12271] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
55 Handzlik G, Holecki M, Kozaczka J, Kukla M, Wyskida K, Kędzierski L, Pawlicki K, Duława J. Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. Pharmacol Rep 2019;71:183-8. [PMID: 30780126 DOI: 10.1016/j.pharep.2018.10.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
56 Conjeevaram Selvakumar PK, Kabbany MN, Alkhouri N. Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. Paediatr Drugs. 2018;20:315-329. [PMID: 29740791 DOI: 10.1007/s40272-018-0292-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
57 Alisi A, Locatelli M, Nobili V. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 2010;13:397-402. [PMID: 20531177 DOI: 10.1097/MCO.0b013e32833aae84] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
58 Alisi A, Carpino G, Nobili V. Paediatric nonalcoholic fatty liver disease: . Current Opinion in Gastroenterology 2013;29:279-84. [DOI: 10.1097/mog.0b013e32835ff95e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
59 Zöhrer E, Alisi A, Jahnel J, Mosca A, Della Corte C, Crudele A, Fauler G, Nobili V. Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial. Appl Physiol Nutr Metab 2017;42:948-54. [PMID: 28511023 DOI: 10.1139/apnm-2016-0689] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
60 Nobili V, Svegliati-baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: Recent insights. Journal of Hepatology 2013;58:1218-29. [DOI: 10.1016/j.jhep.2012.12.003] [Cited by in Crossref: 106] [Cited by in F6Publishing: 99] [Article Influence: 11.8] [Reference Citation Analysis]
61 Alkhouri N, Feldstein AE. The TONIC trial: a step forward in treating pediatric nonalcoholic fatty liver disease. Hepatology 2012;55:1292-5. [PMID: 22461076 DOI: 10.1002/hep.24767] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
62 Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 2013;39:179-90. [PMID: 23528671 DOI: 10.1016/j.diabet.2013.02.006] [Cited by in Crossref: 105] [Cited by in F6Publishing: 91] [Article Influence: 11.7] [Reference Citation Analysis]
63 Xiang Z, Chen YP, Ma KF, Ye YF, Zheng L, Yang YD, Li YM, Jin X. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013;13:140. [PMID: 24053454 DOI: 10.1186/1471-230x-13-140] [Cited by in Crossref: 59] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
64 Mitchel EB, Lavine JE. Review article: the management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40:1155-1170. [PMID: 25267322 DOI: 10.1111/apt.12972] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
65 Suri A, Song E, van Nispen J, Voigt M, Armstrong A, Murali V, Jain A. Advances in the Epidemiology, Diagnosis, and Management of Pediatric Fatty Liver Disease. Clin Ther 2021;43:438-54. [PMID: 33597074 DOI: 10.1016/j.clinthera.2021.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3478/wjg.v20.i7.1712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Rector RS, Thyfault JP. Does physical inactivity cause nonalcoholic fatty liver disease? J Appl Physiol (1985). 2011;111:1828-1835. [PMID: 21565984 DOI: 10.1152/japplphysiol.00384.2011] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
68 Lonardo A, Bellentani S, Ratziu V, Loria P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol 2011;5:279-89. [PMID: 21476922 DOI: 10.1586/egh.11.19] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
69 Nobili V, Sanyal AJ. Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. J Gastroenterol 2012;47:29-36. [PMID: 21983927 DOI: 10.1007/s00535-011-0467-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
70 Della Corte C, Alisi A, Saccari A, De Vito R, Vania A, Nobili V. Nonalcoholic fatty liver in children and adolescents: an overview. J Adolesc Health. 2012;51:305-312. [PMID: 22999829 DOI: 10.1016/j.jadohealth.2012.01.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
71 Della Corte C, Alisi A, Iorio R, Alterio A, Nobili V. Expert opinion on current therapies for nonalcoholic fatty liver disease. Expert Opin Pharmacother. 2011;12:1901-1911. [PMID: 21639814 DOI: 10.1517/14656566.2011.587123] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
72 Darwish Murad S, Metselaar HJ. The invasion of fatty liver disease in liver transplantation. Transpl Int 2016;29:416-7. [PMID: 26497817 DOI: 10.1111/tri.12707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
73 Hattar LN, Wilson TA, Tabotabo LA, Smith EO, Abrams SH. Physical activity and nutrition attitudes in obese Hispanic children with non-alcoholic steatohepatitis. World J Gastroenterol 2011; 17(39): 4396-4403 [PMID: 22110265 DOI: 10.3748/wjg.v17.i39.4396] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
74 Wang X, Xia J, Jiang C. Role of gut microbiota in the development of non-alcoholic fatty liver disease. Liver Research 2019;3:25-30. [DOI: 10.1016/j.livres.2019.01.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Doycheva I, Loomba R. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). Adv Ther. 2014;31:30-43. [PMID: 24385405 DOI: 10.1007/s12325-013-0084-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
76 Pacifico L, Anania C, Martino F, Poggiogalle E, Chiarelli F, Arca M, Chiesa C. Management of metabolic syndrome in children and adolescents. Nutrition, Metabolism and Cardiovascular Diseases 2011;21:455-66. [DOI: 10.1016/j.numecd.2011.01.011] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]